Fundamentals of and Critical Issues in Lipid Autacoid Medicine: A Review
Open Access
- 19 June 2017
- journal article
- review article
- Published by Springer Nature in Pain and Therapy
- Vol. 6 (2) , 153-164
Abstract
The identification of a number of families of lipid signal molecules since the 1990s created new therapeutic possibilities for a great number of disorders characterized by chronic inflammation and pain. These lipid autacoids have been explored in a great variety of animal models related to inflammation, pain, (neuro-)protection, and repair. Based on the data from these models, as well as on a number of proof of principle studies in the clinic in indications such as neuropathic pain, a new chapter in medicine is about to begin. We would like to introduce the term “Autacoid Pain Medicine” for this chapter. There are, however, a number of methodological and strategic issues to overcome in this field. One of the roadblocks is related to patent strategies around families of these molecules. As this is not always recognized we will present a number of examples.Keywords
This publication has 60 references indexed in Scilit:
- Chronic idiopathic axonal neuropathy and pain, treated with the endogenous lipid mediator palmitoylethanolamide: a case collectionInternational Medical Case Reports Journal, 2013
- Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common ColdInternational Journal of Inflammation, 2013
- Inhibition of endocannabinoid degradation in experimental endotoxemia reduces leukocyte adhesion and improves capillary perfusion in the gutJournal of Basic and Clinical Physiology and Pharmacology, 2013
- Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case seriesJournal of Pain Research, 2012
- Resolvin E1 Inhibits Neuropathic Pain and Spinal Cord Microglial Activation Following Peripheral Nerve InjuryJournal of Neuroimmune Pharmacology, 2012
- Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressantsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2011
- Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actionsNature Medicine, 2010
- Blockade of Endocannabinoid-Degrading Enzymes Attenuates Neuropathic PainThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Endocannabinoids and cannabinoid receptors in ischaemia–reperfusion injury and preconditioningBritish Journal of Pharmacology, 2008
- Finding of endocannabinoids in human eye tissues: Implications for glaucomaBiochemical and Biophysical Research Communications, 2005